Interviews on biotechnology

Hubert Birner TVM Capital Bio Europe 2017

Interview 13 Nov 2017

Where is the Money Going in Biotech? A Peek into European VC Strategy

Hubert Birner, Managing Partner at TVM Capital Life Science, discusses his strategy to adapt to the European funding constraints and the areas with most potential for biotech investment. TVM Capital Life Science is a venture capital firm focusing on biotech, pharma and medtech. With over €900M under management and offices in both Munich and Montreal, TVM […]

November 13, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Evotec CEO Werner Lanthaler Biotech Innovation Partnerships

Interview 9 Nov 2017

Interview with Europe’s Leader in Biotech Partnerships

I talked with Werner Lanthaler, CEO of Evotec, during Bio Europe 2017 to ask him what the key is to his company’s great success in supporting biotech innovation and establishing strategic partnerships. Evotec started off as a contract research organization in Hamburg back in 1993. Today it has over 2,000 employees worldwide, its own pipeline […]

November 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 9 Nov 2017

Meet the Spin-Out Queen Taking on Neurological Diseases

Mary Kerr, CEO of NeRRe and Managing Director of KanDy, told us how its approaches could change the face of therapies for neuronal hypersensitivity and women’s health indications. Mary Kerr’s career has taken her through the rigorous world of big pharma, which she says gave her “the skillset… the development, the exposure and the opportunity to work […]

November 9, 2017 - 4 minutesmins - By Alex Dale

Interview 8 Nov 2017

Interviewing Europe’s Most Intense Investor about Trends in Biotech

I interviewed Kate Bingham of SV Health Investors about Alzheimer’s, checkpoint inhibitors, gender diversity and more at BIO Europe. BIO Europe 2017 was off to a racing start on Monday morning when I chatted with Kate Bingham, Managing Partner of SV Health Investors, formerly SV Life Sciences. Since she joined the firm in 1991, she […]

November 8, 2017 - 6 minutesmins - By Evelyn Warner

CureVac Moderna Therapeutics Biotech Unicorn Battle mRNA

Interview 6 Nov 2017

Battle of the Biotech Unicorns: CureVac vs. Moderna

An interview never seen before. We brought together the founders and CEOs of the two biotech unicorns pioneering mRNA therapy: CureVac in Germany and Moderna Therapeutics in the US. The idea of messenger RNA as a therapy is simple but brilliant: instead of giving a protein to a patient, you give their body the instructions […]

November 6, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Interview 2 Nov 2017

Meet the Top Biotech Investor Who Picked His Career By Accident

Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […]

November 2, 2017 - 4 minutesmins - By Alex Dale

dragan grabulovski interview covagen acquisition

Interview 30 Oct 2017

Meet the Covagen Co-Founder that Closed Europe’s Biggest Acquisition in 2014

Dragan Grabulovski co-founded the biotech that became 2014’s largest acquisition in Europe. I caught up with him to hear about the journey and what happens to a founder after his or her company is acquired. Dragan Grabulovski was doing a PhD in pharmaceutical sciences at ETH Zurich in the group of Dario Neri when he […]

October 30, 2017 - 9 minutesmins - By Evelyn Warner

Interview 26 Oct 2017

Meet John Beadle, the Serial Entrepreneur with the Key to Oncolytic Viruses

Serial entrepreneur John Beadle is now at the helm of PsiOxus, an Oxford biotech with some promising virus-based cancer treatments. Oncolytic viruses have been around for a while without much to show for themselves besides Amgen’s Imlygic, but PsiOxus, one of our top Oxford biotechs, has some ideas to make them bear fruit. The company […]

October 26, 2017 - 8 minutesmins - By Evelyn Warner

Interview 25 Oct 2017

What Could RNA Therapies Do for the Treatment of CNS Disorders?

Evelyn chatted with Thomas de Vlaam to find out what his company, Amylon, is working on and how it hopes to change the field fighting CNS disorders. De Vlaam came up with AT-010, a drug candidate for the treatment of Katwijk‘s disease, during his time at ProQR. When it became clear that he had something […]

October 25, 2017 - 3 minutesmins - By Alex Dale

Interview 23 Oct 2017

The German CEO Pushing for an Immunotherapy to Treat Cancer and HIV

Mariola Söhngen, CEO of Mologen, discusses biotech entrepreneurship in Germany and her company’s unique immunotherapy against both cancer and HIV. Mariola Söhngen has an outstanding track record as an entrepreneur and leader in biotech and pharma. In 1998, after 10 years working with big pharma, she founded her first company, Bootcamp, to help young professionals […]

October 23, 2017 - 8 minutesmins - By Clara Rodríguez Fernández

Interview 16 Oct 2017

Meet the Former Banker at the Helm of Denmark’s Healthcare Giant, Novo Holdings

Kasim Kutay has ridden the biotech investment wave. First, he helped build Morgan Stanley’s European healthcare group, then did the same at Moelis & Co and now he heads Novo Holdings, the majority shareholder of Danish household biotech names NovoZymes and Novo Nordisk. I asked him about the company’s healthcare investment strategy and his CEO […]

October 16, 2017 - 7 minutesmins - By Evelyn Warner

Interview 11 Oct 2017

Are Precision Medicine and Digital Health Here Yet?

I connected online with digital health, genomics and precision medicine expert Vishal Gulati to talk about how the advent of data-based healthcare will reshape how patients are treated. A partner at VC firm Draper Esprit, Vishal Gulati focuses his investments on genomics and digital health. Or, as he describes it, on “companies that create value for patients using the […]

October 11, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us